# Long-Term Safety and Efficacy of Spark-Sponsored Gene Therapies in Males With Hemophilia A

> **NCT03432520** · — · ACTIVE_NOT_RECRUITING · sponsor: **Spark Therapeutics, Inc.** · enrollment: 29 (actual)

## Conditions studied

- Hemophilia A

## Interventions

- **GENETIC:** SPK-8011
- **GENETIC:** SPK-8016

## Key facts

- **NCT ID:** NCT03432520
- **Lead sponsor:** Spark Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-08-14
- **Primary completion:** 2032-12
- **Final completion:** 2032-12
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2024-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03432520

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03432520, "Long-Term Safety and Efficacy of Spark-Sponsored Gene Therapies in Males With Hemophilia A". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03432520. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*